Forecasts of explosive AI progress predict that what researchers call recursive self-improvement is on the horizon. But a ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...
'We really do earnestly believe AI could kill all humans!' ...
Paul Schrader looked visibly moved as his new film “The Basics of Philosophy,” about a professor confronted with his past ...
Alphabet high CapEx spending is prudent given the all-or-nothing nature of the AI race, with data centers retaining value.
Ginkgo Bioworks has pivoted to autonomous lab infrastructure in an attempt to capitalize on emerging AI tailwinds. Read more ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results